Search
Prenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
T-lymphocyte activation antigen CD86
go.drugbank.com/bio_entities/BE0000846TargetHumansAlso acts as an inhibitor of T-cell activation by acting as a ligand for CTLA4, a decoy receptor, thereby blocking CD28-mediated T-cell priming (PubMed:11279501) … Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells (PubMed:
Synonyms: CTLA-4 counter-receptor B7.2Integrin beta-1
go.drugbank.com/bio_entities/BE0003575TargetHumansIntegrin alpha-4/beta-1 is a receptor for VCAM1. It recognizes the sequence Q-I-D-S in VCAM1. Integrin alpha-9/beta-1 is a receptor for VCAM1, cytotactin and osteopontin. … ITGA5:ITGB1 is a receptor for IL1B and binding is essential for IL1B signaling (PubMed:29030430).
Synonyms: Fibronectin receptor subunit betaSerine/threonine-protein kinase TNNI3K
go.drugbank.com/bio_entities/BE0009401TargetHumansMay play a role in cardiac physiology
Synonyms: Cardiac ankyrin repeat kinaseTaurocholic acid
go.drugbank.com/drugs/DB04348ApprovedThe product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. … It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.
Brolucizumab
go.drugbank.com/drugs/DB14864ApprovedInvestigationalBrolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.
Poa pratensis pollen
go.drugbank.com/drugs/DB10366ApprovedPoa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.
Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen MixMedifoxamine
go.drugbank.com/drugs/DB13219ApprovedMedifoxamine was marketed as an atypical antidepressant, with anxiolyitc properties in France, Spain, and Morrocco in the 1990s but was later withdrawn from the market due to it causing cases of hepatotoxicity
Fosaprepitant
go.drugbank.com/drugs/DB06717ApprovedInvestigationalIt aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Categories: Neurokinin-1 Receptor Antagonists, Substance P/Neurokinin-1 Receptor AntagonistChloroform
go.drugbank.com/drugs/DB11387ApprovedVet approvedWithdrawnChloroform is an organic small molecule, member of the family of the chloromethanes that presents a formula of CHCl3. … Chloroform is part of the FDA drug products withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]